Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASMUT) non-small-cell lung cancers (NSCLCs) exhibit heterogeneous outcomes, driven by differences in underlying biology shaped by co-mutations. In contrast to KRASG12C NSCLC, KRASG12D NSCLC is associated with low/never-smoking status and is largely uncharacterized.

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Ambrogio, C;
2022

Abstract

Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASMUT) non-small-cell lung cancers (NSCLCs) exhibit heterogeneous outcomes, driven by differences in underlying biology shaped by co-mutations. In contrast to KRASG12C NSCLC, KRASG12D NSCLC is associated with low/never-smoking status and is largely uncharacterized.
-
-
1
6
G12D; KRAS; NSCLC; PD-(L)1 blockade
Ricciuti, B; Alessi, J V; Elkrief, A; Wang, X; Cortellini, A; Li, Y Y; Vaz, V R; Gupta, H; Pecci, F; Barrichello, A; Lamberti, G; Nguyen, T; Lindsay, J; Sharma, B; Felt, K; Rodig, S J; Nishino, M; Sholl, L M; Barbie, D A; Negrao, M V; Zhang, J; Cherniack, A D; Heymach, J V; Meyerson, M; Ambrogio, C; Jänne, P A; Arbour, K C; Pinato, D J; Skoulidis, F; Schoenfeld, A J; Awad, M M; Luo, J
File in questo prodotto:
File Dimensione Formato  
Ricciuti et al-main copy.pdf

Accesso riservato

Dimensione 2.5 MB
Formato Adobe PDF
2.5 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1874707
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact